ZA200203169B - Redox reversible HCV proteins with native-like conformation. - Google Patents

Redox reversible HCV proteins with native-like conformation.

Info

Publication number
ZA200203169B
ZA200203169B ZA200203169A ZA200203169A ZA200203169B ZA 200203169 B ZA200203169 B ZA 200203169B ZA 200203169 A ZA200203169 A ZA 200203169A ZA 200203169 A ZA200203169 A ZA 200203169A ZA 200203169 B ZA200203169 B ZA 200203169B
Authority
ZA
South Africa
Prior art keywords
conformation
native
hcv proteins
redox reversible
redox
Prior art date
Application number
ZA200203169A
Other languages
English (en)
Inventor
Alfons Bosman
Geert Maertens
Erik Depla
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of ZA200203169B publication Critical patent/ZA200203169B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA200203169A 1999-10-27 2002-04-22 Redox reversible HCV proteins with native-like conformation. ZA200203169B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99870225 1999-10-27

Publications (1)

Publication Number Publication Date
ZA200203169B true ZA200203169B (en) 2003-09-23

Family

ID=30129297

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203169A ZA200203169B (en) 1999-10-27 2002-04-22 Redox reversible HCV proteins with native-like conformation.

Country Status (14)

Country Link
EP (1) EP1224214A1 (zh)
JP (1) JP2003513022A (zh)
CN (1) CN1384839A (zh)
AU (1) AU1144501A (zh)
BR (1) BR0015170A (zh)
CA (1) CA2387666A1 (zh)
CZ (1) CZ20021819A3 (zh)
HU (1) HUP0203195A3 (zh)
MX (1) MXPA02004052A (zh)
NZ (1) NZ518095A (zh)
PL (1) PL354990A1 (zh)
RU (1) RU2002109480A (zh)
WO (1) WO2001030815A1 (zh)
ZA (1) ZA200203169B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001273348A1 (en) * 2000-07-10 2002-01-21 Diosynth Rtp, Inc. Purification of human troponin i
NZ529324A (en) * 2001-04-24 2005-08-26 Innogenetics N Core-glycosylated HCV envelope proteins made in yeast cells
EP1481984A1 (en) * 2003-05-28 2004-12-01 Innogenetics N.V. Modified hepatitis C virus (HCV) NS5
CN105209616A (zh) * 2013-03-14 2015-12-30 雅培制药有限公司 用于改进的抗体检测的hcv ns3重组抗原及其突变体
EP3756648A1 (en) * 2019-06-27 2020-12-30 Imnate Sarl Improved vaccine formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
AU652919B2 (en) * 1989-06-02 1994-09-15 Genetic Systems Corporation Cysteine thiol-protected peptides for use in immunoassays
BR9506059A (pt) * 1994-07-29 1997-10-28 Innogenetics Nv Proteinas envelopes purificadas de virus c para uso de diagnóstico e terapêutico
GB9703406D0 (en) * 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
EP0947525A1 (en) * 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue

Also Published As

Publication number Publication date
HUP0203195A3 (en) 2004-07-28
AU1144501A (en) 2001-05-08
MXPA02004052A (es) 2002-11-07
JP2003513022A (ja) 2003-04-08
HUP0203195A2 (hu) 2002-12-28
WO2001030815A1 (en) 2001-05-03
EP1224214A1 (en) 2002-07-24
CZ20021819A3 (cs) 2003-06-18
CA2387666A1 (en) 2001-05-03
RU2002109480A (ru) 2004-03-10
PL354990A1 (en) 2004-03-22
CN1384839A (zh) 2002-12-11
NZ518095A (en) 2003-09-26
BR0015170A (pt) 2002-06-25

Similar Documents

Publication Publication Date Title
AU7739700A (en) Tailored garment with integral support unit
ZA200105484B (en) Polypeptide variants with altered effector function.
DE60026352D1 (en) Biosensor
ZA200204127B (en) New aminopropylphosphinic acids.
HK1049429A1 (en) Infant formula with improved protein content.
AU3678100A (en) Biosensor
ZA200000894B (en) 4-Phenyl-pyridine derivatives.
ZA200201055B (en) Amino-triazolopyridine derivatives.
AU6349800A (en) Direct response e-mail
ZA200109595B (en) 13-methyl-erythromycin derivatives.
HK1046411A1 (en) 5-Phenyl-pyrimidine derivatives.
MXPA02001969A (es) Nuevas moleculas similares a interferon beta.
ZA200200300B (en) Substituted phenoxyacetic acids.
ZA200108646B (en) Electrodes.
ZA200203169B (en) Redox reversible HCV proteins with native-like conformation.
ZA200200263B (en) Drive.
IL140326A0 (en) Protein c derivatives
ZA200201276B (en) 3-Amino-2-phenyl-propane derivatives.
ZA200110454B (en) Pharmaceutical complex.
AU5016200A (en) Diabetes gene
ZA992018B (en) Banners.
AU1362101A (en) Novel traf family proteins
MXPA01011285A (es) Derivados de tio-oxindol.
IL148931A0 (en) Redox reversible hcv proteins with native-like conformation
AU6983000A (en) Chimeric proteins